Assessment of Metabolic Scores for Visceral Fat and the Risk of Cardiovascular Disease in Adults with Stages 0–3 of CKM Syndrome: Findings from a Longitudinal CHARLS Study - Scorecard - MDSpire

Assessment of Metabolic Scores for Visceral Fat and the Risk of Cardiovascular Disease in Adults with Stages 0–3 of CKM Syndrome: Findings from a Longitudinal CHARLS Study

  • By

  • Hao Zhang

  • Shun Li

  • Junpeng Kan

  • Tingting Xia

  • Ning Cao

  • Hui Chen

  • January 17, 2026

  • 0 min

Share

Clinical Scorecard: Assessment of Metabolic Scores for Visceral Fat and the Risk of Cardiovascular Disease in Adults with Stages 0–3 of CKM Syndrome: Findings from a Longitudinal CHARLS Study

At a Glance

CategoryDetail
ConditionCardiovascular-Kidney-Metabolic (CKM) syndrome
Key MechanismsInsulin Resistance (IR) linking visceral adiposity, endothelial dysfunction, and cardiovascular disease (CVD)
Target PopulationAdults with CKM syndrome stages 0–3
Care SettingCommunity-based cohort study

Key Highlights

  • METS-VF integrates multiple metrics to assess visceral fat and metabolic dysfunction.
  • CVD risk increases with CKM syndrome progression from stages 0 to 3.
  • Insulin sensitivity (eGDR) mediates the relationship between METS-VF and CVD.

Guideline-Based Recommendations

Diagnosis

  • Utilize METS-VF for assessing cardiometabolic risk in CKM syndrome.

Management

  • Focus on managing metabolic abnormalities and monitoring visceral fat.

Monitoring & Follow-up

  • Regular follow-ups for incident CVD in CKM syndrome patients.

Risks

  • Increased risk of CVD with advancing CKM syndrome stages.

Patient & Prescribing Data

Adults with CKM syndrome stages 0–3 from the CHARLS cohort.

Targeted interventions should consider metabolic profiles and visceral fat metrics.

Clinical Best Practices

  • Incorporate METS-VF in routine assessments for CKM syndrome.
  • Monitor insulin sensitivity as part of cardiovascular risk management.

References

Original Source(s)

Related Content